Fast Retailing Shares Drop as Uniqlo Japan August Sales Fall 
Berkshire Hathaway Eyes Bigger Stakes in Japan’s Top Trading Houses 
Volkswagen Approves 50,000 More Job Cuts in Major Restructuring 
BP Names Ian Tyler Permanent Chairman After Governance Shake-Up 
Microsoft to Reveal Azure Revenue in Major Reporting Shake-Up 
GSM Eyes US, Europe Expansion Ahead of 2028 Hong Kong IPO 
Tesla Cybercab Launch Puts Robotaxi Ambitions in Focus 
Shein Shares Drop 5% After Weak Hong Kong IPO Debut 
OpenAI Launches GPT-6 Astra With Advanced AI Agent Capabilities 
Thomson Reuters C-Track Cyberattack Hits Courts Across U.S. and Canada 
Nvidia Eyes $2.5 Billion Investment in Thinking Machines Lab 
Adobe Names Anil Chakravarthy CEO as AI Push Accelerates 
US Tech Giants’ AI Bond Boom Raises Euro Zone Borrowing Risks 
Deutsche Telekom Shares Rise as Elliott Pushes Against T-Mobile Merger 
OpenAI Rejects Apple Trade Secret Theft Claims 
Lenovo Shares Fall After Dropbox Security Breach Exposes ID Vulnerability 
Add as a preferred source on Google
SAN CARLOS, Calif., March 07, 2018 -- Iovance Biotherapeutics, Inc. (NASDAQ:IOVA), a biotechnology company developing novel cancer immunotherapies based on tumor-infiltrating lymphocyte (TIL) technology, today announced that company management will present at two investor conferences in March:
- Cowen 38th Annual Health Care Conference in Boston, MA on Wednesday, March 14, 2018 at 10:40 a.m. ET
- Oppenheimer’s 28th Annual Healthcare Conference in New York, NY on Wednesday, March 21, 2018 at 11:30 a.m. ET
A live audio webcast of both presentations will be available by visiting the Investors section of Iovance Biotherapeutics' website at http://ir.iovance.com/. A replay of the webcasts will be archived on Iovance Biotherapeutics’ website for 30 days following the presentations.
About Iovance Biotherapeutics, Inc.
Iovance Biotherapeutics, Inc. (the Company) is a clinical-stage biotechnology company focused on the development of cancer immunotherapy products for the treatment of various cancers. The Company's lead product candidate is an adoptive cell therapy using TIL technology being investigated for the treatment of patients with metastatic melanoma, recurrent and/or metastatic squamous cell carcinoma of the head and neck, recurrent, metastatic or persistent cervical cancer and locally advanced or metastatic non-small cell lung cancer. For more information, please visit http://www.iovance.com.
Investor Relations Contact:
Sarah McCabe
Stern Investor Relations, Inc.
212-362-1200
[email protected]
Media Contact:
Evan Smith
FTI Consulting
212-850-5622
[email protected]
